Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single‐center pilot study

Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single‐center... INTRODUCTIONAntithrombotic therapy plays an essential role in the prevention of thrombotic complications during percutaneous coronary intervention (PCI) . The benefits of antithrombotic agents must be weighed against their potential risk of hemorrhagic complications, especially in complex PCI and patients with high risk of bleeding . Unfractionated heparin (UFH) and bivalirudin have been used most commonly for anticoagulation in PCI [1]. Bivalirudin, a synthetic reversible direct thrombin inhibitor, can selectively block clot‐bound thrombin, potentially achieving a more potent and more predictable anticoagulant response than UFH . Numerous trials have consistently shown that bivalirudin could reduce bleeding complications compared with UFH . Therefore, bivalirudin appears to be a suitable alternative for anticoagulation in PCI. However, the safety and efficacy of bivalirudin in complex PCI procedure like chronic total occlusion (CTO) lesions are still uncertain.CTO is encountered in 15–30% of patients undergoing diagnostic coronary angiography . Compared to patients without CTO, CTO patients have more comorbidities, more extensive CAD and are more frequently referred for bypass surgery . Successful CTO PCI has been demonstrated to improve quality of life and left ventricular function, and reduce ischemia or the need for subsequent bypass surgery . However, CTO recanalization remains one of the most http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Catheterization and Cardiovascular Interventions Wiley

Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single‐center pilot study

Loading next page...
 
/lp/wiley/bivalirudin-in-percutaneous-coronary-intervention-for-chronic-total-wOANhAdYYM
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
1522-1946
eISSN
1522-726X
D.O.I.
10.1002/ccd.27181
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONAntithrombotic therapy plays an essential role in the prevention of thrombotic complications during percutaneous coronary intervention (PCI) . The benefits of antithrombotic agents must be weighed against their potential risk of hemorrhagic complications, especially in complex PCI and patients with high risk of bleeding . Unfractionated heparin (UFH) and bivalirudin have been used most commonly for anticoagulation in PCI [1]. Bivalirudin, a synthetic reversible direct thrombin inhibitor, can selectively block clot‐bound thrombin, potentially achieving a more potent and more predictable anticoagulant response than UFH . Numerous trials have consistently shown that bivalirudin could reduce bleeding complications compared with UFH . Therefore, bivalirudin appears to be a suitable alternative for anticoagulation in PCI. However, the safety and efficacy of bivalirudin in complex PCI procedure like chronic total occlusion (CTO) lesions are still uncertain.CTO is encountered in 15–30% of patients undergoing diagnostic coronary angiography . Compared to patients without CTO, CTO patients have more comorbidities, more extensive CAD and are more frequently referred for bypass surgery . Successful CTO PCI has been demonstrated to improve quality of life and left ventricular function, and reduce ischemia or the need for subsequent bypass surgery . However, CTO recanalization remains one of the most

Journal

Catheterization and Cardiovascular InterventionsWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off